CoChat
Sign Up
Cited by 239Pharmacovigilance and Adverse Drug ReactionsMetabolism, Diabetes, and CancerBladder and Urothelial Cancer Treatments

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Assessing the Association of Pioglitazone Use and Bladder Cancer Through Drug Adverse Event Reporting

Open access
Piccinni, Carlo, Motola, Domenico, Marchesini, Giulio, Poluzzi, Elisabetta·2011·Diabetes Care
DOI 10.2337/dc10-2412PMC PMC3114317
Open this paper in CoChat — free accountOpen PDF

Abstract

OBJECTIVE: To analyze the association between pioglitazone use and bladder cancer through a spontaneous adverse event reporting system for medications. RESEARCH DESIGN AND METHODS: Case/noncase bladder cancer reports associated with antidiabetic drug use were retrieved from the U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (AERS) between 2004 and 2009 and analyzed by the reporting odds ratio (ROR). RESULTS: Ninety-three reports of bladder cancer were retrieved, corresponding to 138 drug-reaction pairs (pioglitazone, 31; insulin, 29; metformin, 25; glimepiride, 13; exenatide, 8; others, 22). ROR was indicative of a definite risk for pioglitazone (4.30 [95% CI 2.82–6.52]), and a much weaker risk for gliclazide and acarbose, with very few cases being treated with these two drugs (6 and 4, respectively). CONCLUSIONS: In agreement with preclinical and clinical studies, AERS analysis is consistent with an association between pioglitazone and bladder cancer. This issue needs constant epidemiologic surveillance and urgent definition by more specific studies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc10-2412

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

Sorted by citations

Items 201–239 of 239

Related

See all

Metadata

Authors
Piccinni, C., Motola, D., Marchesini, G., & Poluzzi, E.
Affiliations
University of Bologna (IT)
Corresponding author
Poluzzi, Elisabetta
ORCID
Venue
Diabetes Care
Publisher
American Diabetes Association
Published
2011-05-20
Volume
34
Issue
6
Pages
1369-1371
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
DOI
10.2337/dc10-2412
PMC
PMC3114317
OpenAlex
W2133104620
Cited by
239
References
12
Citations by year
2025: 4 · 2024: 3 · 2023: 1 · 2022: 5 · 2021: 5 · 2020: 2 · 2019: 12 · 2018: 18 · 2017: 16 · 2016: 14 · 2015: 20 · 2014: 23 · 2013: 37 · 2012: 60
FWCI
56.32
Type
journal article
Language
en
Open access
Licence
Locations
  • Diabetes Care (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
Keywords
pioglitazone, bladder cancer, drug adverse events, antidiabetic drugs, FDA Adverse Event Reporting System, reporting odds ratio, insulin, metformin, glimepiride, exenatide, gliclazide, acarbose, drug safety
MeSH terms
Pioglitazone, Aged, Aged, 80 and over, Urinary Bladder Neoplasms, Female, Humans, Hypoglycemic Agents, Male, Middle Aged, United States, United States Food and Drug Administration, Adverse Drug Reaction Reporting Systems, Thiazolidinediones

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review